Lv3
389 积分 2024-03-19 加入
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
19小时前
已完结
Artificial intelligence for diabetes care: current and future prospects
2天前
已完结
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention
2天前
已完结
Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes
3天前
已完结
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction
3天前
已完结
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
3天前
已完结
Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study
3天前
待确认
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks
3天前
已完结
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
4天前
已完结
Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial
4天前
已完结
皖公网安备34019202002308
